Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome

Romain Appay, Emeline Tabouret, Mehdi Touat, Catherine Carpentier, Carole Colin, François Ducray, Ahmed Idbaih, Karima Mokhtari, Emmanuelle Uro-Coste, Caroline Dehais, Dominique Figarella-Branger, POLA network, C Desenclos, H Sevestre, P Menei, A Rousseau, T Cruel, S Lopez, M-I Mihai, A Petit, C Adam, F Parker, P Dam-Hieu, I Quintin-Roué, S Eimer, H Loiseau, L Bekaert, F Chapon, D Ricard, C Godfraind, T Khallil, D Cazals-Hatem, T Faillot, C Gaultier, M C Tortel, I Carpiuc, P Richard, W Lahiani, H Aubriot-Lorton, F Ghiringhelli, C A Maurage, C Ramirez, E M Gueye, F Labrousse, O Chinot, L Bauchet, V Rigau, P Beauchesne, G Gauchotte, M Campone, D Loussouarn, D Fontaine, F Vandenbos-Burel, A Le Floch, P Roger, C Blechet, M Fesneau, A Carpentier, J Y Delattre, S Elouadhani-Hamdi, M Polivka, D Larrieu-Ciron, S Milin, P Colin, M D Diebold, D Chiforeanu, E Vauleon, O Langlois, A Laquerriere, F Forest, M J Motso-Fotso, M Andraud, G Runavot, B Lhermitte, G Noel, S Gaillard, C Villa, N Desse, C Rousselot-Denis, I Zemmoura, E Cohen-Moyal, E Uro-Coste, F Dhermain, Romain Appay, Emeline Tabouret, Mehdi Touat, Catherine Carpentier, Carole Colin, François Ducray, Ahmed Idbaih, Karima Mokhtari, Emmanuelle Uro-Coste, Caroline Dehais, Dominique Figarella-Branger, POLA network, C Desenclos, H Sevestre, P Menei, A Rousseau, T Cruel, S Lopez, M-I Mihai, A Petit, C Adam, F Parker, P Dam-Hieu, I Quintin-Roué, S Eimer, H Loiseau, L Bekaert, F Chapon, D Ricard, C Godfraind, T Khallil, D Cazals-Hatem, T Faillot, C Gaultier, M C Tortel, I Carpiuc, P Richard, W Lahiani, H Aubriot-Lorton, F Ghiringhelli, C A Maurage, C Ramirez, E M Gueye, F Labrousse, O Chinot, L Bauchet, V Rigau, P Beauchesne, G Gauchotte, M Campone, D Loussouarn, D Fontaine, F Vandenbos-Burel, A Le Floch, P Roger, C Blechet, M Fesneau, A Carpentier, J Y Delattre, S Elouadhani-Hamdi, M Polivka, D Larrieu-Ciron, S Milin, P Colin, M D Diebold, D Chiforeanu, E Vauleon, O Langlois, A Laquerriere, F Forest, M J Motso-Fotso, M Andraud, G Runavot, B Lhermitte, G Noel, S Gaillard, C Villa, N Desse, C Rousselot-Denis, I Zemmoura, E Cohen-Moyal, E Uro-Coste, F Dhermain

Abstract

Diffuse gliomas are classified according to the 2016 WHO Classification of Tumors of the Central Nervous System, which now defines entities by both histology and molecular features. Somatostatin receptor subtype 2A (SSTR2A) expression has been reported in various solid tumors as associated with favorable outcomes. Its expression has been reported in gliomas with uncertain results regarding its prognostic value. The objective of this study was to assess the prognostic impact of SSTR2A protein expression in a large cohort of grade III and IV gliomas classified according to the updated 2016 WHO classification. We further validated our result with an independent cohort of low grade glioma using dataset generated by The Cancer Genome Atlas (TCGA) Research Network.We analyzed clinical and molecular data from 575 patients. SSTR2A protein expression was evaluated using immunohistochemistry on tissue microarrays. High expression of SSTR2A protein associated with the anaplastic oligodendroglioma IDH-mutant and 1p/19q-codeleted subgroup (p < 0.001). Among these tumors, SSTR2A protein expression was significantly associated with a lower proliferative index, the absence of microvascular proliferation and the absence of necrosis (p < 0.001). Furthermore SSTR2A protein expression associated with better overall survival (p = 0.007) and progression-free survival (p = 0.01) in both univariate and multivariate analysis when adjusted by the age, the presence of necrosis and the mitotic index. Similar results were obtained regarding SSTR2 mRNA expression in the TCGA low grade glioma, subtype IDH-mutant and 1p/19q-codeleted, dataset.SSTR2A might represent an attractive biomarker and therapeutic target in anaplastic oligodendroglioma IDH-mutant and 1p/19q-codeleted specific subgroup. Understanding the implicated molecular pathways may represent a step forward to improve therapeutic approaches.

Keywords: Biomarker; Glioma; Somatostatin receptor subtype 2A (SSTR2A); Therapeutic target.

Conflict of interest statement

Ethics approval and consent to participate

Patients included prospectively in the POLA network have provided their written consent for clinical data collection and genetic analysis according to national and POLA network policies.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Immunohistochemical staining of SSTR2A protein in anaplastic oligodendroglioma IDH-mutant and 1p/19q-codeleted (a) Negative staining (IRS = 0) (b) Weak staining intensity (score = 1) in 20% of the cells (score = 2) corresponding to positive cases with low expression (IRS = 3) (c) High staining intensity (score = 3) in 100% of the cells (score = 4) corresponding to positive cases with high expression (IRS = 12)
Fig. 2
Fig. 2
Distribution of SSTR2A protein expression according to tumor subtype Abbreviations: AIII IDHwt, Anaplastic astrocytoma IDH-wildtype; GB IDHwt, Glioblastoma IDH-wildtype; AIII IDHmut, Anaplastic astrocytoma IDH-mutant; GB IDHmut, Glioblastoma IDH-mutant; OIII, Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted. *** = p < 0.001
Fig. 3
Fig. 3
a Distribution of SSTR2A protein expression according to pathological groups in anaplastic oligodendrogliomas, IDH-mutant and 1p/19q-codeleted. Abbreviation: MVP, microvascular proliferation b Ki-67 labelling index according to SSTR2A protein expression among the anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted. *** = p < 0.001
Fig. 4
Fig. 4
Overall survival and Progression-free survival according to SSTR2A protein expression in anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted. a No SSTR2A expression (IRS = 0) versus low SSTR2A expression (1 ≤ IRS < 4) versus high SSTR2A expression (IRS ≥ 4). b Negative (IRS = 0) versus positive (IRS ≥ 1) SSTR2A expression
Fig. 5
Fig. 5
a Relation between SSTR2 mRNA expression and subtype in low grade glioma patients from TCGA cohort. b Overall survival according to SSTR2 mRNA expression in patients with IDH-mutant and 1p/19q-codeleted low grade gliomas from the TCGA cohort. *** = p < 0.001

References

    1. Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer. 2014;21:R485–R493. doi: 10.1530/ERC-14-0389.
    1. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(Suppl 2):42S–55S. doi: 10.2967/jnumed.110.085753.
    1. Annunziata M, Luque RM, Durán-Prado M, Baragli A, Grande C, Volante M, et al. Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Hum Reprod. 2012;27:2117–2129. doi: 10.1093/humrep/des144.
    1. Bielle F, Ducray F, Mokhtari K, Dehais C, Adle-Biassette H, Carpentier C, et al. Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas. Brain Pathol. 2017;27:567–579. doi: 10.1111/bpa.12434.
    1. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–816. doi: 10.1007/s00259-012-2330-6.
    1. Bowman RL, Wang Q, Carro A, Verhaak RGW, Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro-Oncology. 2017;19:139–141. doi: 10.1093/neuonc/now247.
    1. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. 2008;28:264–278. doi: 10.1523/JNEUROSCI.4178-07.2008.
    1. Cancer Genome Atlas Research Network. Brat DJ, RGW V, Aldape KD, WKA Y, Salama SR, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372:2481–2498. doi: 10.1056/NEJMoa1402121.
    1. Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, et al. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab. 2013;98:E1730–E1739. doi: 10.1210/jc.2013-2145.
    1. Ducray F, Idbaih A, de Reyniès A, Bièche I, Thillet J, Mokhtari K, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer. 2008;7:41. doi: 10.1186/1476-4598-7-41.
    1. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76:620–627. doi: 10.1002/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>;2-S.
    1. Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, et al. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. Neuro-Oncology. 2014;16:1244–1254. doi: 10.1093/neuonc/nou047.
    1. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13:822–840. doi: 10.2741/2722.
    1. Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer. 2011;18:R233–R251. doi: 10.1530/ERC-10-0334.
    1. Heute D, Kostron H, von Guggenberg E, Ingorokva S, Gabriel M, Dobrozemsky G, et al. Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC. J Nucl Med. 2010;51:397–400. doi: 10.2967/jnumed.109.072819.
    1. Kim HS, Lee HS, Kim WH. Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors. Cancer Res Treat. 2011;43:181–188. doi: 10.4143/crt.2011.43.3.181.
    1. Kiviniemi A, Gardberg M, Kivinen K, Posti JP, Vuorinen V, Sipilä J, et al. Somatostatin receptor 2A in gliomas: association with oligodendrogliomas and favourable outcome. Oncotarget. 2017;8:49123. doi: 10.18632/oncotarget.17097.
    1. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology. 1968;83:783–790. doi: 10.1210/endo-83-4-783.
    1. Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett. 2013;6:821–828. doi: 10.3892/ol.2013.1435.
    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1.
    1. Mawrin C, Schulz S, Pauli SU, Treuheit T, Diete S, Dietzmann K, et al. Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas. J Neuropathol Exp Neurol. 2004;63:13–19. doi: 10.1093/jnen/63.1.13.
    1. Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999;5:1025–1033.
    1. Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, et al. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013;119:4094–4102. doi: 10.1002/cncr.28341.
    1. Pola S, Cattaneo MG, Vicentini LM. Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J Biol Chem. 2003;278:40601–40606. doi: 10.1074/jbc.M306510200.
    1. Raggi CC, Maggi M, Renzi D, Calabrò A, Bagnoni ML, Scaruffi P, et al. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab. 2000;85:3866–3873.
    1. Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci. 2013;34:676–688. doi: 10.1016/j.tips.2013.10.001.
    1. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29:486–493. doi: 10.1007/s00259-001-0717-x.
    1. Song KB, Kim SC, Kim JH, Seo D-W, Hong S-M, Park K-M, et al. Prognostic value of somatostatin receptor subtypes in pancreatic neuroendocrine tumors. Pancreas. 2016;45:187–192. doi: 10.1097/MPA.0000000000000493.
    1. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135. doi: 10.1056/NEJMoa1607427.
    1. Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol. 2016;132:625–634. doi: 10.1007/s00401-016-1611-8.
    1. Tang X, Takekoshi S, Itoh J, Umemura S, Shoji S, Terachi T, et al. Somatostatin analogue inhibits the mobility of prostate carcinoma cells: a new therapeutic method for advanced prostate carcinoma. Int J Oncol. 2010;37:1077–1083.
    1. Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34:228–252. doi: 10.1016/j.yfrne.2013.07.005.
    1. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. doi: 10.1016/j.ccr.2009.12.020.
    1. Vitali E, Cambiaghi V, Zerbi A, Carnaghi C, Colombo P, Peverelli E, et al. Filamin-a is required to mediate SST2 effects in pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23:181–190. doi: 10.1530/ERC-15-0358.
    1. Vyberg M, Ulhøi BP, Teglbjaerg PS. Neuronal features of oligodendrogliomas--an ultrastructural and immunohistochemical study. Histopathology. 2007;50:887–896. doi: 10.1111/j.1365-2559.2007.02686.x.
    1. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315–e329. doi: 10.1016/S1470-2045(17)30194-8.
    1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. doi: 10.1056/NEJMoa0808710.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren